With the stock market heating up again, consider investing in disruptive stocks to buy. Betting on disruptive stocks, especially at the right prices, can prove incredibly rewarding. Moreover, with expectations of a sustained bull run ahead, you'd be remiss to ignore the three disruptive stock bets at current prices. Disruptive stocks to buy have the potential to revolutionize their respective industries through their innovative prowess. For investors who can see the potential of disruptive stocks, these bus ...

Hims & Hers Health, Inc. (HIMS) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this company have returned +8.3% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Medical Info Systems industry, to which Hims & Hers Health belongs, has lost 9.1% over this period. Now the key question is: Where could the stock be headed in the near term?Alt ...

Key PointsCall option buyers think Starbucks, Pfizer, and Him & Hers Health stocks could see higher prices relatively quickly.All three stocks are offering unjustifiable discounts to their 52-week high prices, becoming targets for options traders. Analysts see at least a double-digit upside through their price targets today, backing these traders up.Options are complicated and not for the faint of heart. While some investors may use them to take on irresponsible leverage levels on their minor positions, oth ...

A six-point argument that shares are a table-pounding opportunity worth scooping up now.Telehealth company Hims & Hers Health (HIMS -4.88%) found itself immersed in controversy recently after some polarizing social media posts by the company's CEO sparked debate. The stock took a bit of a hit as a result Then the company released first-quarter earnings amid the uproar, giving bulls a lot to cheer about.While it's often a bad idea for a company to go anywhere near political discussions, there are enough reas ...

The stock is one of the cheapest high-growth stocks around.Shares of Hims & Hers Health (HIMS -4.88%) jumped following the company's first-quarter earnings report that once again announced surging revenue growth. That performance has helped the stock perform well this year, up about 40%.Let's look at some recent comments from the CEO that caused the stock to dip, the company's recent quarterly results, and whether it's too late to buy the stock.Controversial comments sink stock ahead of earningsHims & Hers ...

Prostock-Studio/iStock via Getty ImagesIntroduction It's been a wild few days for Hims & Hers (NYSE:HIMS) stock. Last Friday, CEO Andrew Dudum posted several controversial tweets on X, one of which included his support for university students to protest "against the genocide of the Palestinian people & for your university's divestment from Israel". This sparked a lot of rage and panic among the investing community, sending HIMS stock 8% lower in a single trading day. Even Shark Tank Co-host Kevin O'Lear ...

Hims & Hers Health, Inc. (HIMS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following yea ...

Strong earnings have sent this healthcare company higher today.Shares of growth stock Hims & Hers Health (HIMS 7.38%) jumped as much as 17.1% in trading on Tuesday after the company reported first-quarter 2024 financial results. As of 3 p.m. ET, shares were holding about an 8.4% gain for the day.Crushing expectationsHims & Hers said revenue for the quarter jumped 46% from a year ago to $278.2 million and sailed past the $268.7 million that analysts were expecting. The company also reported net income of $11 ...

Key PointsShares of Hims & Hers stock rallied double after announcing the company's first quarter 2024 results. Investors now have additional evidence to support a bullish company thesis that could run for the next decade.Bullish EPS projections and price targets suggest the stock still needs to be done rallying.5 stocks we like better than Technology Select Sector SPDR FundShares of Hims & Hers Health Inc. NYSE: HIMS are jumping by as much as 15.5% after the company released its first quarter 2024 earnings ...